Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Goy

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumMichael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Nature Medicine|July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H Wilson, Ryan M Young, Roland Schmitz, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
The Lancet. Haematology|June 27, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialNagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
JCI Insight|February 11, 2021
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasmaMichele L Donato, Steven Park, Melissa Baker, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumMichael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Nature Medicine|July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H Wilson, Ryan M Young, Roland Schmitz, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
The Lancet. Haematology|June 27, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialNagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
JCI Insight|February 11, 2021
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasmaMichele L Donato, Steven Park, Melissa Baker, et al.
Pageof 17